Theravance Biopharma, Inc.
TBPH
$9.75
$0.212.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.22% | 13.40% | -105.26% | -105.11% | -106.33% |
| Total Depreciation and Amortization | -0.47% | 1.75% | -7.90% | -4.87% | -12.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.43% | 118.42% | 102.63% | 102.55% | 102.74% |
| Change in Net Operating Assets | 344.06% | -94.41% | -94.97% | -113.40% | -119.69% |
| Cash from Operations | 57.27% | 92.35% | 94.83% | 90.24% | 85.56% |
| Capital Expenditure | 86.66% | 60.57% | 58.73% | -30.24% | -334.97% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -55.62% | -66.93% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 139.77% | -142.31% | -98.69% | -97.43% | -102.76% |
| Cash from Investing | 137.57% | -157.12% | -98.77% | -97.46% | -102.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -1.94% | -18.82% | -22.21% | -22.82% | -22.82% |
| Repurchase of Common Stock | 98.44% | 83.69% | 75.97% | 22.47% | -50.86% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.74% | 83.93% | 92.87% | 82.25% | 73.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.32% | 86.07% | -423.71% | -243.44% | -224.21% |